Clinical trial · Interventional
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00583830CI-TRIAL-00011666NSCLCcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Mapatumumab | Biological | — | UNRESOLVED |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- A
- description
- Paclitaxel and carboplatin
- interventionNames
- Drug: Paclitaxel
- Drug: Carboplatin
- type
- EXPERIMENTAL
- label
- B
- description
- Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
- interventionNames
- Biological: Mapatumumab
- Drug: Paclitaxel
- Drug: Carboplatin
- type
- EXPERIMENTAL
- label
- C
- description
- Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically confirmed stage IIIB or stage IV advanced primary non-small cell lung cancinoma * Age 18 years or older Exclusion Criteria: * Received investigational (not yet approved by a regulatory authority) or non-investigational agent to treat Lung Cancer * Received radiation therapy within 4 weeks before randomization * Major surgery within 4 weeks before randomization * Minor surgery within 2 weeks before randomizaiton * Systemic steroids within 1 week before randomization * Any grade 2 or greater neuropathy * History of severe (Grade 4) hypersensitivity reaction to products containing Cremophor EL (cyclosporine, teniposide) * History of any infection requiring hospitalization or antibiotics within 2 weeks before randomization * Known brain or spinal cord metastases * History of other cancers within 5 years before randomization * Known HIV, hepatitis-B or hepatitis-C infection * Pregnant or breast-feeding women * Previously treated with Mapatumumab
References
Publications (1)
- DERIVEDvon Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL, Camidge DR. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2014 May;15(3):188-196.e2. doi: 10.1016/j.cllc.2013.12.005. Epub 2013 Dec 27. PMID 24560012